Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cedric Hermans

Showing results (111-120 of 222) with videos related to

Pageof 23
Sort By:
Thrombosis and Haemostasis|September 4, 2008
The JAK2 V617F mutation is not a cause of central retinal vein occlusionCedric Hermans, Véronique Slachmuylder, Jean-Luc Gala, et al.
The Lancet. Haematology|March 13, 2026
Balancing the benefits and risks of rebalancing coagulation in haemophiliaCedric Hermans, Quentin Van Thillo, Glenn F Pierce, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 6, 2018
UK Haemophilia Centre Doctors' Organisation guidance on the use of extended-half-life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treatersCedric Hermans, An Van Damme, Gerry Dolan, et al.
BMC Molecular and Cell Biology|May 16, 2021
Impact of uORFs in mediating regulation of translation in stress conditionsSimone G Moro, Cedric Hermans, Jorge Ruiz-Orera, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 13, 2019
Inhibitor epidemiology and genetic-related risk factors in people with haemophilia from Côte d'IvoireCatherine Lambert, Nathalie Lannoy, N'Dogomo Meité, et al.
Critical Reviews in Oncology/Hematology|April 7, 2022
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspectiveCedric Hermans, Mark T Reding, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 10, 2019
Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?Simona Raso, Catherine Lambert, Ana Boban, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2019
Real-life experience in switching to new extended half-life products at European haemophilia centresFlora Peyvandi, Isabella Garagiola, Marco Boscarino, et al.
Pharmacoeconomics - Open|March 23, 2024
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in GermanyNiklaus Meier, Hendrik Fuchs, Katya Galactionova, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 4, 2008
Continuous intravenous infusion of a low-molecular-weight heparin during allogenic haematopoietic stem-cell transplantationAnca Boeras, Catherine Lambert, Augustin Ferrant, et al.
Pageof 23

Showing results (111-120 of 222) with videos related to

Sort By:
Pageof 23
Thrombosis and Haemostasis|September 4, 2008
The JAK2 V617F mutation is not a cause of central retinal vein occlusionCedric Hermans, Véronique Slachmuylder, Jean-Luc Gala, et al.
The Lancet. Haematology|March 13, 2026
Balancing the benefits and risks of rebalancing coagulation in haemophiliaCedric Hermans, Quentin Van Thillo, Glenn F Pierce, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 6, 2018
UK Haemophilia Centre Doctors' Organisation guidance on the use of extended-half-life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treatersCedric Hermans, An Van Damme, Gerry Dolan, et al.
BMC Molecular and Cell Biology|May 16, 2021
Impact of uORFs in mediating regulation of translation in stress conditionsSimone G Moro, Cedric Hermans, Jorge Ruiz-Orera, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 13, 2019
Inhibitor epidemiology and genetic-related risk factors in people with haemophilia from Côte d'IvoireCatherine Lambert, Nathalie Lannoy, N'Dogomo Meité, et al.
Critical Reviews in Oncology/Hematology|April 7, 2022
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspectiveCedric Hermans, Mark T Reding, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 10, 2019
Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?Simona Raso, Catherine Lambert, Ana Boban, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2019
Real-life experience in switching to new extended half-life products at European haemophilia centresFlora Peyvandi, Isabella Garagiola, Marco Boscarino, et al.
Pharmacoeconomics - Open|March 23, 2024
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in GermanyNiklaus Meier, Hendrik Fuchs, Katya Galactionova, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 4, 2008
Continuous intravenous infusion of a low-molecular-weight heparin during allogenic haematopoietic stem-cell transplantationAnca Boeras, Catherine Lambert, Augustin Ferrant, et al.
Pageof 23